Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) EPS (Weighted Average and Diluted) (2021 - 2025)

Heron Therapeutics' EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.01 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 150.0% year-over-year to -$0.01; the TTM value through Dec 2025 reached -$0.12, down 33.33%, while the annual FY2025 figure was -$0.12, 33.33% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.01 in Q4 2025 per HRTX's latest filing, up from -$0.1 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.02 in Q4 2024 to a low of -$0.63 in Q1 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.23, with a median of -$0.13 recorded in 2022.
  • The largest YoY upside for EPS (Weighted Average and Diluted) was 150.0% in 2025 against a maximum downside of 233.33% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.53 in 2021, then soared by 75.47% to -$0.13 in 2022, then surged by 61.54% to -$0.05 in 2023, then surged by 140.0% to $0.02 in 2024, then crashed by 150.0% to -$0.01 in 2025.
  • Per Business Quant, the three most recent readings for HRTX's EPS (Weighted Average and Diluted) are -$0.01 (Q4 2025), -$0.1 (Q3 2025), and -$0.02 (Q2 2025).